Risk reduced for worsening heart failure or cardiovascular death, regardless of frailty index class
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, April 25, 2022 (HealthDay News) -- Dapagliflozin reduces the risk for worsening heart failure or cardiovascular death, regardless of frailty status, according to a study published online April 26 in the Annals of Internal Medicine.
Jawad H. Butt, M.D., from the University of Glasgow in the United Kingdom, and colleagues examined the efficacy of dapagliflozin according to frailty status in a post-hoc analysis of the phase 3 randomized Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial. Patients with symptomatic heart failure with a left ventricular ejection fraction of 40 percent or less and elevated natriuretic peptide were enrolled and randomly assigned to the addition of either once-daily dapagliflozin or placebo to guideline-recommended therapy.
The frailty index (FI) was calculable for 4,742 patients: 50.4, 33.9, and 15.7 percent were in class 1, 2, and 3, respectively (not frail, more frail, and most frail). Patients were followed for a median of 18.2 months. The researchers found that regardless of FI class, dapagliflozin reduced the risk for worsening heart failure or cardiovascular death. For dapagliflozin versus placebo, the differences in event rate per 100 person-years were −3.5, −3.6, and −7.9, respectively, from lowest to highest FI class. For other clinical events and health status, consistent benefits were observed, but the most frail patients generally had larger absolute reductions.
"These findings are important considering the common reluctance of clinicians to introduce medications to patients that are perceived to be frail," the authors write.
The study was funded by AstraZeneca, the manufacturer of dapagliflozin.
From Your Site Articles
- SGLT2 Inhibitors Reduce Heart Failure Hospitalization - Consumer ... ›
- Long-Lasting Cardiovascular Burden Seen After COVID-19 ... ›
- Bereavement Tied to Higher Risk for Death Among Heart Failure Patients - Consumer Health News | HealthDay ›
- Mediterranean Diet Tied to Frailty Prevention - Consumer Health News | HealthDay ›
- Heart Failure-Related Deaths Up in Younger Adults in the U.S. - Consumer Health News | HealthDay ›
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022
Read this Next
Other Trending Articles